160391-70-8 Usage
Description
TYRPHOSTIN AG 1290 is a small molecule inhibitor that targets the enzyme tyrosinase, which is involved in the melanin biosynthesis pathway. It is a potent and selective inhibitor of tyrosinase, making it a valuable tool for studying the regulation of melanogenesis and the function of melanocytes.
Uses
Used in Pharmaceutical Industry:
TYRPHOSTIN AG 1290 is used as a research tool for studying the regulation of melanogenesis and the function of melanocytes. It is particularly useful in understanding the role of tyrosinase in melanin production and its potential as a therapeutic target for conditions related to melanin dysregulation, such as hyperpigmentation and certain types of skin cancer.
Used in Cosmetic Industry:
TYRPHOSTIN AG 1290 is used as an active ingredient in skin care products for its potential skin-lightening and anti-pigmentation properties. By inhibiting tyrosinase, it can help reduce the production of melanin, which may lead to a more even skin tone and a reduction in the appearance of age spots, sunspots, and other hyperpigmented areas.
Used in Research and Development:
TYRPHOSTIN AG 1290 is used as a chemical probe in the development of new drugs and therapies targeting melanogenesis-related disorders. Its potent and selective inhibition of tyrosinase makes it a valuable compound for identifying potential therapeutic agents and understanding the underlying mechanisms of melanin regulation.
Check Digit Verification of cas no
The CAS Registry Mumber 160391-70-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,3,9 and 1 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 160391-70:
(8*1)+(7*6)+(6*0)+(5*3)+(4*9)+(3*1)+(2*7)+(1*0)=118
118 % 10 = 8
So 160391-70-8 is a valid CAS Registry Number.
160391-70-8Relevant articles and documents
Development of blood-brain barrier permeable nitrocatechol-based catechol O-methyltransferase inhibitors with reduced potential for hepatotoxicity
Silva, Tiago,Mohamed, Tarek,Shakeri, Arash,Rao, Praveen P.N.,Martínez-Gonzalez, Loreto,Pérez, Daniel I.,Martínez, Ana,Valente, Maria Jo?o,Garrido, Jorge,Uriarte, Eugenio,Serr?o, Paula,Soares-Da-silva, Patrício,Remi?o, Fernando,Borges, Fernanda
, p. 7584 - 7597 (2016/09/04)
Recent efforts have been focused on the development of centrally active COMT inhibitors, which can be valuable assets for neurological disorders such as Parkinson's disease, due to the severe hepatotoxicity risk associated with tolcapone. New nitrocatechol COMT inhibitors based on naturally occurring caffeic acid and caffeic acid phenethyl ester were developed. All nitrocatechol derivatives displayed potent inhibition of peripheral and cerebral COMT within the nanomolar range. Druglike derivatives 13, 15, and 16 were predicted to cross the blood-brain barrier in vitro and were significantly less toxic than tolcapone and entacapone when incubated at 50 μM with rat primary hepatocytes. Moreover, their unique acidity and electrochemical properties decreased the chances of formation of reactive quinone-imines and, as such, the potential for hepatotoxicity. The binding mode of 16 confirmed that the major interactions with COMT were established via the nitrocatechol ring, allowing derivatization of the side chain for future lead optimization efforts.
